PARMAR KUSH
SEC Form 4 insider trading activity
PARMAR KUSH has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 10, 2026.
On the most recent filing, PARMAR KUSH is listed as Director at Entrada Therapeutics, Inc. Inside the rolling window, PARMAR KUSH reported no open-market purchases and 6 open-market sales totaling $3.6M in TRDA. The largest disclosed transaction in the window is a sale of 200,000 TRDA shares on Nov 14, 2025, worth $1.8M.
Companies traded
Other insiders at TRDA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.6M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has PARMAR KUSH made?
PARMAR KUSH has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does PARMAR KUSH trade?
PARMAR KUSH has filed SEC Form 4 disclosures for 1 company, including TRDA.
When was PARMAR KUSH's most recent SEC Form 4 filing?
PARMAR KUSH's most recent SEC Form 4 filing on Tracefour is dated Aug 10, 2026.
What is PARMAR KUSH's total buy and sell value in the current window?
Inside the rolling retention window, PARMAR KUSH bought $0 and sold $3.6M based on SEC Form 4 filings.
What was PARMAR KUSH's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 200,000 TRDA shares on 2025-11-14, worth $1.8M, per SEC Form 4 filings.